Structure Therapeutics, Inc. Sponsored ADR (GPCR) AI Stock Analysis

• Market Cap: $1.02B
• Dividend Yield: N/A
• Average Volume (3M): 702.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.15
• Revenue Growth: N/A
• EPS Growth: 7.57%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 57,536,750
• 10 Day Avg. Volume: 740,573
• 30 Day Avg. Volume: 702,526
• PEG Ratio: >-0.01
• Price to Book (P/B): -99.14
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -246.69
• Enterprise Value/Market Cap: 11.06
• Enterprise Value/Revenue: 4.26K
• Enterprise Value/Gross Profit: -48.87K
• Enterprise Value/Ebitda: -18.81
• 1Y Price Target: $78.82
• Price Target Upside: 342.81% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12

• Rating: 31 Underperform
• Price Target: ―

Structure Therapeutics, Inc.'s overall score is largely impacted by its financial performance, reflecting significant financial sustainability risks due to zero revenues and increasing losses, despite strong cash positions. The technical analysis provides a mixed view with some short-term momentum but longer-term concerns. The valuation remains challenging with a negative P/E ratio, indicating a speculative investment reliant on future success in R&D and commercialization.

Positive Factors

Clinical Trials

Aleniglipron exhibits structural uniqueness, with slightly distinct properties that could drive differentiated weight-loss outcomes in the ACCESS trials.

Financial Position

Management reported a cash balance of $836.9M, which is expected to fund operations through at least 2027.

Negative Factors

Market Competition

Pharmacy benefit manager (PBM) access remains a challenge for incremental entrants in this space.

Market Positioning

An important consideration for oral obesity treatments is how Lilly will position orforglipron alongside tirzepatide and whether oral GLP-1 therapies can carve out a meaningful role given the entrenched dominance of injectable formulations.

Structure Therapeutics, Inc. Sponsored ADR Business Overview & Revenue Model

Company Description

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

How the Company Makes Money

Structure Therapeutics, Inc. generates revenue through the development and commercialization of its drug candidates. The company makes money by advancing its compounds through clinical trials and seeking regulatory approval for market entry. Once approved, these drugs can be licensed or sold to pharmaceutical companies or healthcare providers, generating income through sales, royalties, or milestone payments. Additionally, the company may engage in strategic partnerships or collaborations with other biopharmaceutical firms, which can provide funding, shared resources, and expertise in exchange for a share in the profits or rights to market the developed therapies. These partnerships and collaborations often play a significant role in the company's revenue model, offering both financial support and expanded market reach.

Structure Therapeutics, Inc. Sponsored ADR Financial Statement Overview

Summary

Structure Therapeutics, Inc. is in a typical biotechnology growth phase with heavy reliance on external financing to support operations and R&D, evident from zero revenues and increasing losses. While the balance sheet shows strong liquidity due to financing, the absence of operating income and negative cash flows underscore financial sustainability risks. Investors must consider the company's future ability to generate revenue and control costs as it progresses through its development pipeline.

Income Statement

The company has consistently reported zero revenue over the analyzed periods, indicating a lack of commercial product or service sales, typical for early-stage biotech firms. Net losses have widened significantly from $15,876 in 2020 to $122,526,000 in 2024, showing increased expenses likely related to R&D and operational scaling. This trajectory signals an aggressive investment phase with high cash burn without immediate income generation.

Balance Sheet

The balance sheet shows strong cash positions with cash and equivalents increasing from $37,445 in 2020 to $883,518,000 in 2024, largely due to financing activities, which is crucial for the company's operations given the lack of revenue. The debt-to-equity ratio has improved as equity turned positive in recent years, but total debt remains low compared to equity, indicating low leverage. However, the negative historical equity values raise concerns about prior financial stability.

Cash Flow

Operating cash flow remains negative, reflecting the company's ongoing investment in R&D and operations without corresponding income. Free cash flow is consistently negative, indicating continued cash burn. The company relies heavily on financing activities to fund operations, as evidenced by significant cash inflows from financing. This dependency poses a risk if future financing rounds are not successful.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-231.74K	0.00	-949.17K	-623.26K	-266.35K	-20.03K
EBITDA	-181.48M	-158.23M	-102.46M	-52.28M	-37.62M	-15.75M
Net Income	-143.32M	-122.53M	-89.62M	-51.32M	-38.05K	-15.88K
Balance Sheet
Total Assets	866.55M	903.33M	482.02M	97.84M	111.16K	38.70K
Cash, Cash Equivalents and Short-Term Investments	836.88M	883.52M	467.32M	90.84M	107.31K	37.45K
Total Debt	7.59M	3.86M	5.45M	260.00K	621.00	280.00
Total Liabilities	41.91M	38.49M	29.05M	212.99M	175.89K	61.17K
Stockholders Equity	824.64M	864.84M	452.97M	-115.14M	-64.73K	-22.47K
Cash Flow
Free Cash Flow	-136.23M	-117.93M	-81.66M	-46.27M	-33.37K	-14.30K
Operating Cash Flow	-134.78M	-116.64M	-79.49M	-46.12M	-32.16K	-14.28K
Investing Cash Flow	-326.29M	-358.91M	-268.34M	-62.11M	17.86K	-21.15K
Financing Cash Flow	514.68M	515.26M	451.53M	29.01M	103.25K	25.84K

Structure Therapeutics, Inc. Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 17.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GPCR, the sentiment is Negative. The current price of 17.8 is below the 20-day moving average (MA) of 18.58, below the 50-day MA of 20.56, and below the 200-day MA of 25.84, indicating a bearish trend. The MACD of -0.83 indicates Negative momentum. The RSI at 31.53 is Neutral, neither overbought nor oversold. The STOCH value of 14.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GPCR.

Structure Therapeutics, Inc. Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥354.97B	10.64	-2.99%	2.47%	11.68%	-10.27%
WVE	55 Neutral	$1.29B	―	-171.41%	―	-14.98%	-51.76%
NRIX	52 Neutral	$844.00M	―	-50.67%	―	41.86%	10.48%
DYN	43 Neutral	$1.40B	―	-61.32%	―	―	14.93%
ETNB	42 Neutral	$1.39B	―	-69.30%	―	―	-68.13%
ELVN	36 Underperform	$1.11B	―	-31.30%	―	―	12.85%
GPCR	31 Underperform	$1.02B	―	-22.88%	―	―	7.57%

Structure Therapeutics, Inc. Sponsored ADR Corporate Events

Structure Therapeutics Advances Obesity Treatment Candidate

Structure Therapeutics Inc. has announced the selection of ACCG-2671, an oral small molecule amylin receptor agonist, as its lead candidate for obesity treatment. Preclinical studies show ACCG-2671’s effectiveness in weight loss with a favorable safety profile, supporting once-daily dosing. The company plans to initiate Phase 1 clinical trials by the end of 2025. This advancement positions Structure Therapeutics as a leader in developing amylin-based treatments that could significantly impact the treatment landscape for obesity and related conditions.